Cbmr The neurokinin 2 receptor (NK2R) is a key player in regulating energy balance, with research increasingly focusing on its potential as a therapeutic target for metabolic diseases. As part of the broader neurokinin receptor family, NK2R is activated by neuropeptides like neurokinin A (NKA), a peptide that plays a crucial role in controlling appetite and energy expenditure. Understanding the intricate mechanisms of NK2R activation and signaling is paramount for developing novel treatments that can effectively manage conditions such as obesity.
The neurokinin 2 receptor (NK2R), also known as TACR2, is a G protein-coupled receptor that preferentially binds to natural peptide ligands.Background: NK2R.Nucleostemin is a protein found in the nucleoli of embryonic stem cells, adult CNS stem cells, primitive cells in the bone marrow and ... This receptor is a significant component of the neurokinin receptor family, which comprises three distinct members. NK2R is primarily activated by neurokinin A (NKA), a neuropeptide that influences various physiological processes. Research indicates that activation of NK2R can suppress appetite centrally and concurrently boost energy expenditure peripherally. This dual action makes NK2R a compelling target for interventions aimed at weight management and the treatment of metabolic disordersThe Challenge: The body's natural activator forNK2R, Neurokinin A (NKA), cannot be used as a drug for two main reasons: 1.Extremely Short Half-life: It breaks ....
The therapeutic implications of targeting NK2R are becoming increasingly evident, particularly in the realm of obesity treatment. Selective NK2R peptide agonists have demonstrated the ability to increase energy expenditure, reduce fat mass, and suppress appetite in preclinical studies. This suggests a promising avenue for developing new weight loss medications. Unlike some existing peptide-based drugs, NK2R agonists that are small molecules could offer a more cost-effective production pathway, potentially making them more accessible. Furthermore, drugs targeting NK2R may provide significant weight loss benefits for individuals who do not respond adequately to current treatmentsHiTSeeker NK2 Tachykinin Receptor Cell Line.
Despite the promising therapeutic potential, developing effective NK2R-based drugs faces certain challenges. The body's natural activator for NK2R, Neurokinin A (NKA), has a very short half-life, making it unsuitable for direct therapeutic use.作者：PA Perez·2025—selective NK2R peptide agonist increases energy expenditure, reduces fat mass, and. 73 suppresses appetite, highlighting its therapeutic ... NKA is a linear peptide composed of 10 amino acids, and its rapid degradation in the body limits its efficacy as a drug.Anti-Substance-K receptor/NK2R Antibody (A30847) This limitation necessitates the development of more stable synthetic agonists or antagonists that can effectively modulate NK2R activity without the pharmacokinetic drawbacks of NKA. Researchers are exploring NK2R small molecules and peptides designed to overcome these issues, aiming for improved stability and therapeutic effectiveness.Neurokinin receptors and their implications in various autoimmune ...
Advancing the understanding and therapeutic application of NK2R relies on a range of research tools and reagents.Deciphering specificity and cross-reactivity in tachykinin ... These include various NK2R antibodies, which are crucial for detecting and quantifying the receptor in biological samples across different model species like bovine, human, and rat.Peptide Design Competition Blocking peptides, such as the Neurokinin 2 Receptor/NK2R Blocking Peptide, are also vital2024年11月13日—The group identified the receptor through genetic screens that suggested NK2R playeda role in maintaining energy balanceand glucose control. “ .... These peptides bind to and inhibit NK2R antibodies, serving as essential negative controls to confirm the specificity of antibody-based detection methodsDeciphering specificity and cross-reactivity in tachykinin .... Additionally, cell lines engineered to express NK2R are valuable for high-throughput screening of potential drug candidates and for studying receptor signaling pathways. The development of selective NK2R agonists, like EB1002, which has been shown to enhance the expression of genes related to mitochondrial biogenesis and energy expenditure in obese mouse models, further underscores the importance of these research toolsTopological analysis of the complex formed between ....
Emerging research highlights the critical role of NK2R in maintaining energy balance and glucose control. Genetic screens have implicated NK2R in these fundamental physiological processes.Neurokinin 2 Receptor (NK2R) Polyclonal Antibody Targeting NK2R has shown potential in reversing cardiometabolic dysfunction. For instance, studies in obese mice and monkeys with diabetes demonstrated that an agonist of the neurokinin 2 receptor induced weight loss and increased energy expenditure. This suggests that modulating NK2R activity could be a viable strategy for addressing complex metabolic conditions.Anti-NK2R Antibody (A101358) The receptor's influence extends to intestinal lipid mobilization, further emphasizing its comprehensive role in metabolic regulation.
The ongoing research into NK2R signifies a burgeoning field with substantial potential for clinical impact. Future efforts are likely to focus on designing more potent and selective NK2R modulators, whether they are peptide-based or small molecule compoundsChallenging activity and signaling bias in tachykinin NK1 .... Understanding the precise structural interactions between NK2R and its ligands, including NKA and synthetic compounds, is crucial for rational drug designTACR2 / NK2R Antibody - Anti-Neurokinin A Receptor ...Synthetic 20 amino acid peptidefrom 2nd extracellular domain of human Neurokinin A Receptor.. Further investigation into the signaling pathways downstream of NK2R activation will also provide deeper insights into its physiological roles and therapeutic leverage. As research progresses, the development of effective NK2R-targeting therapies could offer new hope for treating obesity and related metabolic diseases, potentially providing a novel alternative to existing treatmentsThe Challenge: The body's natural activator forNK2R, Neurokinin A (NKA), cannot be used as a drug for two main reasons: 1.Extremely Short Half-life: It breaks ....
Join the newsletter to receive news, updates, new products and freebies in your inbox.